Device Trial Radar · NCT04186546
Zephyr Valve Registry (ZEVR)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 25, 2019
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Pulmonx CorporationPublic (LUNG)
- Sponsor type
- Industry
- First posted
- Dec 4, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
Conditions
- Emphysema
Interventions
Zephyr Valve ProcedureDevice
The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate of Pneumothorax from Baseline to 45-days post-procedureTime frame: Baseline to 45-days post-procedure
- Incidence Rate of Serious Adverse Events (SAEs) of Interest from Baseline to 3 years post-procedureTime frame: Baseline to 3 years post-procedure
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Chicago
Chicago, Illinois
Northwestern Medicine
Winfield, Illinois
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.